RECURRENT EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Clinical trials for RECURRENT EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR explained in plain language.
Never miss a new study
Get alerted when new RECURRENT EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR trials appear
Sign up with your email to follow new studies for RECURRENT EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…
Matched conditions: RECURRENT EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…
Matched conditions: RECURRENT EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: RECURRENT EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC